PrintFriendly
Industry News
|
Monday, June 18, 2018  The update reported on a Phase 1/2 clinical trial for the company’s investigational therapy for the treatment of patients with severe hemophilia B/factor IX (FIX) deficiency. |
|
Friday, June 8, 2018  The new web portal for patients and caregivers is intended to provide timely and accurate information on targeted serious adverse events of interest for HEMLIBRA. |
|
Wednesday, June 6, 2018  This priority review is specifically for adults and children with hemophilia A without FVIII inhibitors. |
|
Tuesday, June 5, 2018  The new vial size is 3500 IU (international unit). |
|
Monday, June 4, 2018  The data showed its hemophilia B investigational gene therapy candidate AMT-060 could be successfully delivered to patients with certain pre-existing antibodies. |
|
Wednesday, May 23, 2018  The overall annualized bleeding rate for all 15 participants was reduced by 98% to an annual rate of 0.2 bleeds per patient. |
|
Wednesday, May 23, 2018  In the Phase III HAVEN 3 study, patients who received HEMLIBRA prophylaxis every week or every two weeks experienced a 96% and 97% reduction in treated bleeds. |
|
Tuesday, April 17, 2018 The designation is for people with hemophilia A without inhibitors. |
|
Monday, April 16, 2018  ICER is an independent and non-partisan research organization that evaluates the clinical and economic value of prescription drugs, medical tests, and other healthcare and healthcare delivery innovations. |
|
Monday, April 16, 2018  The company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B. |